Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 2 N=29 S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Adult Meningioma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 Participants
Phase 2 N=178 Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Brain and Central Nervous System Tumors
Primary: Progression-free Survival Rate at 3 Years — 92.2; 93.7; 58.8 percentage of participants
Phase 2 N=34 Monthly SOM230C for Recurrent or Progressive Meningioma
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Phase 2 N=18 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Phase 2 N=23 Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Adult Grade I Meningioma · Adult Grade II Meningioma · Adult Grade III Meningioma
Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants
Phase 3 N=80 Magnesium and Intraoperative Blood Loss in Meningioma Surgery
Meningioma
Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315
Phase 2 N=50 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Phase 2 N=90 Trabectedin for Recurrent Grade II/III Meningioma
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Phase 2 N=50 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Acoustic Schwannoma · Adult Anaplastic Meningioma · Adult Ependymoma
Primary: Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months — 93; 85; 51; 73 percentage of patients
Phase 2 N=25 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Phase 2 N=21 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Glioblastoma · Gliosarcoma
Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants
Phase 4 N=256 Phase IV Bioseal Study in Brain Tumor Surgery
Hemostasis · Meningioma Surgery
Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…
Phase 3 N=108 Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Meningioma
Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…
Phase 2 N=12 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants
Phase 2 N=20 A Pilot Study of Bevacizumab for Neoplastic Meningitis
Neoplastic Meningitis
Primary: Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells — 93 percentage of participants
Phase 2 N=110 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
N/A N=376 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Phase 3 N=165 Idiopathic Intracranial Hypertension Treatment Trial
Idiopathic Intracranial Hypertension
Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=40 Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
Glioma
Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
N/A N=12 PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Early Phase 1 N=6 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants